Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study
暂无分享,去创建一个
Maryse Lapeyre-Mestre | J. Fournier | M. Lapeyre-Mestre | A. Sommet | J. Montastruc | S. Oustric | A. Pathak | Atul Pathak | Agnès Sommet | R. Bourrel | Jean-Louis Montastruc | Jean-Pascal Fournier | Robert Bourrel | Stéphane Oustric
[1] A. Fourrier-Réglat,et al. The CADEUS study: burden of nonsteroidal anti-inflammatory drug (NSAID) utilization for musculoskeletal disorders in blue collar workers. , 2009, British journal of clinical pharmacology.
[2] J. Krzesinski. Hypertension artérielle et facteurs de risque , 2004 .
[3] N. Kressin,et al. Intensifying Therapy for Hypertension Despite Suboptimal Adherence , 2009, Hypertension.
[4] Ward Hj,et al. Inadequate management of blood pressure in a hypertensive population. , 1999 .
[5] A. Dominiczak,et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. , 2007, Journal of hypertension.
[6] F. Veglio,et al. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study , 2002, Journal of hypertension.
[7] D. Felson,et al. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. , 1993, Archives of internal medicine.
[8] K. Ferdinand,et al. Realities of Newer β‐Blockers for the Management of Hypertension , 2009, Journal of clinical hypertension.
[9] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[10] M. Mattila,et al. Pharmacokinetics of Oxicam Nonsteroidal Anti-Inflammatory Agents , 1994, Clinical pharmacokinetics.
[11] B. Bégaud,et al. Pharmacoepidemiological research using French reimbursement databases: yes we can! , 2010, Pharmacoepidemiology and drug safety.
[12] P. McGettigan,et al. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies , 2011, PLoS medicine.
[13] N. Poulter,et al. The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. , 2006, Journal of hypertension.
[14] K. Knights,et al. Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. , 2010, British journal of clinical pharmacology.
[15] T. Lang,et al. Poor blood pressure control in general practice: in search of explanations. , 2009, Archives of cardiovascular diseases.
[16] L. Køber,et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. , 2009, Archives of internal medicine.
[17] S. Marinopoulos,et al. Failure to Intensify Antihypertensive Treatment by Primary Care Providers: A Cohort Study in Adults with Diabetes Mellitus and Hypertension , 2008, Journal of General Internal Medicine.
[18] Utilization of health care databases for pharmacoepidemiology , 2012, European Journal of Clinical Pharmacology.
[19] P. Lapuerta,et al. Physician-related barriers to the effective management of uncontrolled hypertension. , 2002, Archives of internal medicine.
[20] F. Ruschitzka,et al. Acetaminophen Increases Blood Pressure in Patients With Coronary Artery Disease , 2010, Circulation.
[21] C Michael Stein,et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study , 2002, The Lancet.
[22] P. Conlin,et al. Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients , 2000, Hypertension.
[23] S. Snowden,et al. The Effects of Nonsteroidal Anti-Inflammatory Drugs on Blood Pressure in Hypertensive Patients , 2011, Cardiology in review.
[24] R. Day,et al. Non-steroidal anti-inflammatory drugs , 2019, Reactions Weekly.
[25] A. Dominiczak,et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.
[26] L. Køber,et al. The pattern of use of non‐steroidal anti‐inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people , 2008, Pharmacoepidemiology and drug safety.
[27] R. Maas,et al. Antihypertensive therapy: special focus on drug interactions , 2003, Expert opinion on drug safety.
[28] L. Køber,et al. Risk of Myocardial Infarction and Death Associated With the Use of Nonsteroidal Anti‐Inflammatory Drugs (NSAIDs) Among Healthy Individuals: A Nationwide Cohort Study , 2009, Clinical pharmacology and therapeutics.
[29] R. Day,et al. Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis , 1994, Annals of Internal Medicine.
[30] J. Dartigues,et al. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three‐City (3C) Study , 2009, Pharmacoepidemiology and drug safety.
[31] T. Stürmer,et al. Non-steroidal anti-inflammatory drugs , 2003 .
[32] S. Samson,et al. Traitement médicamenteux de l'hypertension artérielle et des facteurs de risque cardiovasculaire : quelles évolutions entre 2000 et 2005 ? , 2007 .
[33] W. White,et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. , 2002, The American journal of cardiology.